Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 45.63% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 94.17% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/24/2023 | 45.63% | 吹笛者桑德勒 | → 15 美元 | 啟動覆蓋範圍 | → 超重 |
| 02/07/2023 | 94.17% | 查丹資本 | → 20 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
樂團生物醫學控股 (OBIO) 的目標價格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $15.00 expecting OBIO to rise to within 12 months (a possible 45.63% upside). 2 analyst firms have reported ratings in the last year.
管弦樂團生物醫學控股有限公司（納斯達克股票代碼：OBIO）的最新價格目標是由派珀·桑德勒於 2023 年 2 月 24 日報導。該分析師公司設定了 15.00 美元的價格目標，預計 OBIO 將在 12 個月內上升至（可能為 45.63％ 的上行情況）。2 分析師公司在去年報告了評級。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
樂團生物醫學控股 (OBIO) 的最新分析師評分為何？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Piper Sandler, and Orchestra BioMed Hldgs initiated their overweight rating.
樂團生物醫學控股（NASDAQ：OBIO）的最新分析師評級由派珀·桑德勒提供，樂團生物醫學控股發起了他們的超重評級。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
樂團生物醫學控股（OBIO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析師進行了廣泛的研究，其中包括通過公共財務報表，與樂團 BioMed Hldgs 的高管和客戶交談，以及聆聽盈利電話會議後到達股票評級。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。樂團生物醫學控股的最後評級於 2023 年 2 月 24 日提交，因此您應該期望下一個評分將在 2024 年 2 月 24 日左右提供。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析師評級管弦樂團生物醫學控股（OBIO）是否正確？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a initiated with a price target of $0.00 to $15.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $10.30, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的樂團生物醫學控股（OBIO）評級已啟動，目標價格為 0.00 美元至 15.00 美元。目前的價格管弦樂團生物醫學控股（OBIO）的交易價格為 $10.30，這是分析師的預測範圍內。